vs
Side-by-side financial comparison of Adient plc (ADNT) and Zoetis (ZTS). Click either name above to swap in a different company.
Adient plc is the larger business by last-quarter revenue ($3.6B vs $2.4B, roughly 1.5× Zoetis). Zoetis runs the higher net margin — 25.3% vs -0.6%, a 25.9% gap on every dollar of revenue. On growth, Adient plc posted the faster year-over-year revenue change (4.3% vs 3.0%). Zoetis produced more free cash flow last quarter ($732.0M vs $15.0M). Over the past eight quarters, Zoetis's revenue compounded faster (4.4% CAGR vs -1.4%).
Adient plc is an American, Irish-domiciled company that operates as the largest manufacturer of automotive seating for customers worldwide and is based in Plymouth, Michigan, United States.
Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total re...
ADNT vs ZTS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.6B | $2.4B |
| Net Profit | $-22.0M | $603.0M |
| Gross Margin | 6.0% | 70.2% |
| Operating Margin | 1.1% | 31.9% |
| Net Margin | -0.6% | 25.3% |
| Revenue YoY | 4.3% | 3.0% |
| Net Profit YoY | — | 3.8% |
| EPS (diluted) | $-0.28 | $1.37 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.6B | $2.4B | ||
| Q3 25 | $3.7B | $2.4B | ||
| Q2 25 | $3.7B | $2.5B | ||
| Q1 25 | $3.6B | $2.2B | ||
| Q4 24 | $3.5B | $2.3B | ||
| Q3 24 | $3.6B | $2.4B | ||
| Q2 24 | $3.7B | $2.4B | ||
| Q1 24 | $3.8B | $2.2B |
| Q4 25 | $-22.0M | $603.0M | ||
| Q3 25 | $18.0M | $721.0M | ||
| Q2 25 | $36.0M | $718.0M | ||
| Q1 25 | $-335.0M | $631.0M | ||
| Q4 24 | $0 | $581.0M | ||
| Q3 24 | $79.0M | $682.0M | ||
| Q2 24 | $-11.0M | $624.0M | ||
| Q1 24 | $-70.0M | $599.0M |
| Q4 25 | 6.0% | 70.2% | ||
| Q3 25 | 6.7% | 71.5% | ||
| Q2 25 | 6.3% | 73.6% | ||
| Q1 25 | 7.2% | 72.0% | ||
| Q4 24 | 6.2% | 69.5% | ||
| Q3 24 | 6.9% | 70.6% | ||
| Q2 24 | 5.6% | 71.7% | ||
| Q1 24 | 6.1% | 70.6% |
| Q4 25 | 1.1% | 31.9% | ||
| Q3 25 | 1.7% | 37.0% | ||
| Q2 25 | 1.8% | 36.7% | ||
| Q1 25 | -7.3% | 36.5% | ||
| Q4 24 | 1.3% | 31.6% | ||
| Q3 24 | 1.8% | 36.6% | ||
| Q2 24 | 1.2% | 33.0% | ||
| Q1 24 | -1.1% | 34.1% |
| Q4 25 | -0.6% | 25.3% | ||
| Q3 25 | 0.5% | 30.0% | ||
| Q2 25 | 1.0% | 29.2% | ||
| Q1 25 | -9.3% | 28.4% | ||
| Q4 24 | — | 25.1% | ||
| Q3 24 | 2.2% | 28.6% | ||
| Q2 24 | -0.3% | 26.4% | ||
| Q1 24 | -1.9% | 27.4% |
| Q4 25 | $-0.28 | $1.37 | ||
| Q3 25 | $0.17 | $1.63 | ||
| Q2 25 | $0.43 | $1.61 | ||
| Q1 25 | $-3.99 | $1.41 | ||
| Q4 24 | $0.00 | $1.29 | ||
| Q3 24 | $0.88 | $1.50 | ||
| Q2 24 | $-0.12 | $1.37 | ||
| Q1 24 | $-0.77 | $1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | $2.4B | — |
| Stockholders' EquityBook value | $1.7B | $3.3B |
| Total Assets | $8.8B | $15.5B |
| Debt / EquityLower = less leverage | 1.37× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | — | $1.4B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $2.0B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $2.0B |
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.4B | — |
| Q4 25 | $1.7B | $3.3B | ||
| Q3 25 | $1.8B | $5.4B | ||
| Q2 25 | $1.8B | $5.0B | ||
| Q1 25 | $1.7B | $4.7B | ||
| Q4 24 | $1.9B | $4.8B | ||
| Q3 24 | $2.1B | $5.2B | ||
| Q2 24 | $1.9B | $5.0B | ||
| Q1 24 | $2.1B | $5.1B |
| Q4 25 | $8.8B | $15.5B | ||
| Q3 25 | $9.0B | $15.2B | ||
| Q2 25 | $8.8B | $14.5B | ||
| Q1 25 | $8.6B | $14.1B | ||
| Q4 24 | $8.5B | $14.2B | ||
| Q3 24 | $9.4B | $14.4B | ||
| Q2 24 | $9.1B | $14.2B | ||
| Q1 24 | $9.3B | $14.3B |
| Q4 25 | 1.37× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.34× | — | ||
| Q1 25 | 1.44× | — | ||
| Q4 24 | 1.28× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.24× | — | ||
| Q1 24 | 1.16× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $80.0M | $893.0M |
| Free Cash FlowOCF − Capex | $15.0M | $732.0M |
| FCF MarginFCF / Revenue | 0.4% | 30.7% |
| Capex IntensityCapex / Revenue | 1.8% | 6.7% |
| Cash ConversionOCF / Net Profit | — | 1.48× |
| TTM Free Cash FlowTrailing 4 quarters | $174.0M | $2.3B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.0M | $893.0M | ||
| Q3 25 | $213.0M | $938.0M | ||
| Q2 25 | $172.0M | $486.0M | ||
| Q1 25 | $-45.0M | $587.0M | ||
| Q4 24 | $109.0M | $905.0M | ||
| Q3 24 | $263.0M | $951.0M | ||
| Q2 24 | $158.0M | $502.0M | ||
| Q1 24 | $81.0M | $595.0M |
| Q4 25 | $15.0M | $732.0M | ||
| Q3 25 | $134.0M | $805.0M | ||
| Q2 25 | $115.0M | $308.0M | ||
| Q1 25 | $-90.0M | $438.0M | ||
| Q4 24 | $45.0M | $689.0M | ||
| Q3 24 | $191.0M | $784.0M | ||
| Q2 24 | $88.0M | $370.0M | ||
| Q1 24 | $12.0M | $455.0M |
| Q4 25 | 0.4% | 30.7% | ||
| Q3 25 | 3.6% | 33.5% | ||
| Q2 25 | 3.1% | 12.5% | ||
| Q1 25 | -2.5% | 19.7% | ||
| Q4 24 | 1.3% | 29.7% | ||
| Q3 24 | 5.4% | 32.8% | ||
| Q2 24 | 2.4% | 15.7% | ||
| Q1 24 | 0.3% | 20.8% |
| Q4 25 | 1.8% | 6.7% | ||
| Q3 25 | 2.1% | 5.5% | ||
| Q2 25 | 1.5% | 7.2% | ||
| Q1 25 | 1.2% | 6.7% | ||
| Q4 24 | 1.8% | 9.3% | ||
| Q3 24 | 2.0% | 7.0% | ||
| Q2 24 | 1.9% | 5.6% | ||
| Q1 24 | 1.8% | 6.4% |
| Q4 25 | — | 1.48× | ||
| Q3 25 | 11.83× | 1.30× | ||
| Q2 25 | 4.78× | 0.68× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | 3.33× | 1.39× | ||
| Q2 24 | — | 0.80× | ||
| Q1 24 | — | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ADNT
Segment breakdown not available.
ZTS
| Other | $1.3B | 56% |
| Livestock | $234.0M | 10% |
| Pain Sedation | $209.0M | 9% |
| Other Pharmaceuticals | $188.0M | 8% |
| Swine | $125.0M | 5% |
| Poultry | $117.0M | 5% |
| Fish | $81.0M | 3% |
| Other Non Pharmaceuticals | $70.0M | 3% |
| Manufactured Product Other | $18.0M | 1% |
| Medicated Feed Additives | $12.0M | 1% |
